Navigation Links
Cancer: Another step towards medication
Date:3/18/2009

This release is available in German.

The gene Myc is an important factor for the growth of organisms by cell division. It causes the production of a protein which, as a transcription factor, controls the expression of up to 15 % of all human genes. When this gene mutates to an oncogene, the cell proliferates excessively and apoptosis is inhibited. Thereby the gene plays a decisive role in the development of many tumors. The problem is that pharmacological substances do not target Myc as it does not have enzymatic activity of its own. Thus, scientists worldwide are trying to find alternative ways to inhibit this oncogene. A team of scientists led by Klaus Bister and Markus Hartl of the Institute of Biochemistry and the Centre for Molecular Biosciences of the University of Innsbruck may have made an important step towards achieving this goal.

Suppressing pathological cell growth

For the first time, the scientists have shown that Myc suppresses the expression of the gene BASP1. This evidence prompted them to test the effect of BASP1 on the oncogene. In cell experiments they proved that BASP1 specifically inhibits the uncontrolled proliferation of Myc. Until now the precise biochemical function of BASP1 is unknown", Professor Bister explains. However, in our experiments we have found clear evidence that Myc-induced cell transformation can be specifically inhibited by BASP1, and consequently, the gene functions as a tumor suppressor." This finding may facilitate the development of new drugs which keep the development of tumors under control.


'/>"/>

Contact: Professor Klaus Bister
klaus.bister@uibk.ac.at
43-512-507-5270
University of Innsbruck
Source:Eurekalert  

Page: 1

Related biology news :

1. Prostate cancer: Watchful wait or vaccinate?
2. Scientists discover how cigarette smoke causes cancer: Study points to new treatments, safer tobacco
3. Stem cells and cancer: cancer pathways that also control the adult stem cell population
4. Hispanic women and breast cancer: An understudied group
5. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors
6. One species entire genome discovered inside anothers
7. Same gene protects from 1 disease, opens door to another
8. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes
9. For good or ill Ireland gains another mammal species
10. Ocean acidification -- another undesired side effect of fossil fuel-burning
11. Viral recombination another way HIV fools the immune system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer: Another step towards medication
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... ... September 21, 2017 , ... Executives ... the world’s most progressive pharma and biotech organizations to do more clinical trials ... and biotech events in Q4. , DrugDev will demonstrate DrugDev Spark™, the world’s ...
(Date:9/21/2017)... SAN DIEGO, CALIF. (PRWEB) , ... September 21, 2017 , ... ... kitchen earlier this month. The organization, a worldwide society of professional women with ... a venue to hold its annual dinner. , Twelve members began with ...
(Date:9/20/2017)... ... September 20, 2017 , ... Cybrexa Therapeutics , a ... the role of chief scientific officer. In this role, Dr. Paralkar will lead ... and CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology and ...
(Date:9/20/2017)... ... September 20, 2017 , ... Proscia ... Pathology , a provider of whole slide imaging solutions, are hosting a pre-conference ... workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” will feature Proscia ...
Breaking Biology Technology: